Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

For reference, Novo Nordisk also offers a highly successful weight loss drug, Wegovy, a GLP-1 receptor agonist.

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Johnna Byrd began taking Zepbound to help her finish the weight loss journey she started. She never imagined it would help ...

In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with ...

CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.